ACL Australian Clinical Labs Ltd
- 2.460
- -0.030-1.20%
Australian Clinical Labs Ltd News
Is It Too Late To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
Australian Clinical Labs Target Price Cut 6.9% to A$3.35/Share by Citi>ACL.AU
Australian Clinical Labs Target Price Cut 6.9% to A$3.35/Share by Citi>ACL.AU
2 ASX 300 Shares Crashing up to 12% on Earnings Updates
Listed below are two ASX 300 shares that are being sold off following the release of their respective releases.
Australian Clinical Labs Slashes Interim Dividend as Underlying H1 FY24 EPS Falls 49%
Australian Clinical Labs (ASX:ACL) reported Wednesday that its underlying earnings per share in the six-month period ended Dec. 31, 2023, were down 49% year over year to AU$0.0511. Statutory EPS fell
Australian Clinical Labs Interim Dividend 3 Australian Cents/Security
Australian Clinical Labs Interim Dividend 3 Australian Cents/Security
Australian Clinical Labs 1H Revenue A$337.3 Million, Down 6.4%
Australian Clinical Labs 1H Revenue A$337.3 Million, Down 6.4%
Medicare Levy Change: 1.2 Million Aussies to Get Extra Tax Boost
Millions of Aussies will be able to avoid or pay a lower Medicare levy under a major change announced by the government.
Is There An Opportunity With Australian Clinical Labs Limited's (ASX:ACL) 36% Undervaluation?
When Can ASX 200 Investors Expect RBA Interest Rate Cuts?
Will interest rates go higher yet from here? Or can ASX 200 investors look forward to some rate-cutting relief from the RBA in 2024?
Australian Clinical Labs Gets Regulator Approval to Withdraw Healius Takeover Offer
Australian Clinical Labs (ASX:ACL) obtained consent from the Australian Securities and Investments Commission to withdraw its AU$1.52 billion takeover offer for fellow pathology firm Healius (ASX:HLS)
US Fed's Dovish Stance Lifts Australian Shares
Australian shares rallied on Friday after the US Federal Reserve signaled an end to its monetary tightening cycle. The S&P/ASX 200 Index rose 64.80 points, or 0.9%, to 7,442.70. "The pivot from the US
ACL: Could Also Offer Regulator Fresh Asset Divestments Alongside a New Offer
ACL: Could Also Offer Regulator Fresh Asset Divestments Alongside a New Offer
ACL: Could Challenge Regulator in Court If It Makes a New Offer
ACL: Could Challenge Regulator in Court If It Makes a New Offer
ACL: Competition Regulator's Opposition Was Not Unexpected
ACL: Competition Regulator's Opposition Was Not Unexpected
ACL Will Not Waive Breach of Offer Conditions Including From Healius's Capital Raise
ACL Will Not Waive Breach of Offer Conditions Including From Healius's Capital Raise
ACL Says Healius's Trading Performance Has Deteriorated
ACL Says Healius's Trading Performance Has Deteriorated
ACL: Concerned That Healius May Report a Significant 1H Loss
ACL: Concerned That Healius May Report a Significant 1H Loss
ACL Withdraws Takeover Offer for Healius, Citing Performance
ACL Withdraws Takeover Offer for Healius, Citing Performance
ACL's Offer to Divest Some Centers Did Not Address Concerns, Regulator Says
ACL's Offer to Divest Some Centers Did Not Address Concerns, Regulator Says
Combined ACL-Healius Would Operate More Than 50% of Approved Pathology Collection Centers, Regulator Says
Combined ACL-Healius Would Operate More Than 50% of Approved Pathology Collection Centers, Regulator Says
Analysis
Price Target
No Data
